Fig. 4: Combination of sorafenib and LZX-2-73 depleted the antioxidative stress response in tumor cells. | Cell Death & Disease

Fig. 4: Combination of sorafenib and LZX-2-73 depleted the antioxidative stress response in tumor cells.

From: Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models

Fig. 4

A The ratio of GSH/GSSG was measured in MIAPaCa-2 cells, MCF-7 cells, and HepG2 cells treated with sorafenib, LZX-2-73, or the combination of the two drugs for 72 h. B Catalase and C SOD activity was measured in MIAPaCa-2 cells treated with sorafenib, LZX-2-7,3, or the combination of the two drugs for 24 h. D Western blot of phospho-NRF2, total NRF2, XCT, GPX4, and actin was performed in MIAPaCa-2 cells treated with sorafenib, LZX-2-7,3, or the combination of the two drugs for 24 or 48 h.

Back to article page